tri semaglutide New obesity drug dubbed 'triple G' appears even more powerful than Wegovy - shedding 25% bodyweight glp1 #pharma #biotech #healthcarestrategy #obesity

Dual NOX/SGLT2 inhibitors as the hybrid compound GKT137831 (inhibitor of NOX1 and NOX4) and empagliflozin (SGLT2 inhibitor) have shown synergistic effects, improving insulin sensitivity by 40% in diabetic rodent models (Karakasis et al., 2025)

Ardeshir-Larijani, F

By Application Why Type 2 Diabetes Management Dominates GLP-1 Applications

Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients

With LillyDirect and unprecedented demand for GLP-1s, the company sees a chance to push beyond traditional payor dynamics and build a self-pay, branded business with staying power beyond a patent cycle